Amneal Pharmaceuticals (AMRX) Amortization of Deferred Charges (2017 - 2026)

Amneal Pharmaceuticals' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 42.89% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $19.5 million (down 32.97% YoY), while the FY2025 annual figure was $22.4 million, down 22.91% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $3.9 million, up from $3.7 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $8.0 million in Q3 2024, with the low at $2.1 million in Q1 2023.
• The 5-year median for Amortization of Deferred Charges is $3.9 million (2026), against an average of $4.4 million.
• The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges jumped 240.03% in 2024, then plunged 45.5% in 2025.
• Amneal Pharmaceuticals' Amortization of Deferred Charges stood at $2.1 million in 2022, then soared by 121.46% to $4.7 million in 2023, then jumped by 46.16% to $6.8 million in 2024, then slumped by 45.5% to $3.7 million in 2025, then climbed by 4.71% to $3.9 million in 2026.
• Business Quant data shows AMRX's Amortization of Deferred Charges at $3.9 million in Q1 2026, $3.7 million in Q4 2025, and $5.0 million in Q3 2025.